EpCAM-targeting CAR-T cell immunotherapy is safe and efficacious for epithelial tumors
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The efficacy of CAR-T cells for solid tumors is unsatisfactory. EpCAM is a biomarker of epithelial tumors, but the clinical feasibility of CAR-T therapy targeting EpCAM is lacking. Here, we report pre- and clinical investigations of EpCAM–CAR-T cells for solid tumors. We demonstrated that EpCAM–CAR-T cells costimulated by Dectin-1 exhibited robust antitumor activity without adverse effects in xenograft mouse models and EpCAM-humanized mice. Notably, in clinical trials for epithelial tumors (NCT02915445), 6 (50%) of the 12 enrolled patients experienced self-remitted grade 1/2 toxicities, 1 patient (8.3%) experienced reversible grade 3 leukopenia, and no higher-grade toxicity reported. Efficacy analysis determined two patients as partial response. Three patients showed >23 months of progression-free survival, among whom one patient experienced 2-year progress-free survival with detectable CAR-T cells 200 days after infusion. These data demonstrate the feasibility and tolerability of EpCAM–CAR-T therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CAR-T cells currently under development for targeting colorectal CSCs include CD133-, EpCAM-, or CD166-directed CAR-T cells [229,230,231,232].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [231]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509 · cited 1×
“The robust release of inflammatory cytokines and the proliferation of CAR-T cells contribute to antitumor efficacy in the treat-ment of hematological malignancies ( 54 ).”
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · cited 2×
“5, A to D), there was no treatment-related CRS in any of the patients as evaluated by former reported CRS diagnosis criteria ( 36 ).”
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533 · cited 2×
“However, potential antigens targeted by CAR-T therapy are not restricted to tumor cells, and they are also expressed on normal tissues, leading to lethal on-target/off-tumor toxicity to normal tissues ( 5 , 6 ).”
Self-citationCirculating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
Yu, M., Bardia, A., Wittner, B. S., Stott, S. L., Smas, M. E., Ting, D. T., Isakoff, S. J., Ciciliano, J. C., Wells, M. N., Shah, A. M., et al. (2013) · Science · doi:10.1126/science.1228522 · Cited by 2,476 · cited 1×
“…EpCAM was expressed on cancer stem cells and circulating tumor cells (CTCs) and was closely associated with tumor recurrence and metastasis ( 11 , 12 ), leading to the approval of EpCAM by the Food and Drug Administration as a diagnostic marker of CTCs of breast, prostate, and colorectal cancers…”
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438 · cited 1×
“Cytokine release syndrome (CRS) is a critical clinical sign of excessive T cell activation and proinflammatory cytokine production and is a key predictor of fatal adverse events in T cell therapy ( 33 ).”
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 1×
“Previous research demonstrated that a memory phenotype is preferable to terminal differentiated effectors in adoptive therapy due to superior proliferation and persistence ( 31 ).”
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, C. E., Alizadeh, D., Starr, R., Weng, L., Wagner, J. R., Naranjo, A., Ostberg, J. R., Blanchard, M. S., Kilpatrick, J., Simpson, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610497 · Cited by 1,836
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815 · cited 1×
“This study demonstrated that EpCAM was feasible as a target for CAR-T therapy. as resulting in antitumor efficacy limitations in vivo ( 30 ).”
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472 · cited 2×
“Therefore, finding the balance between affinity and function may improve treatment safety by ensuring the efficiency of recognition ( 4 ).”
Kawalekar, O. U., O’Connor, R. S., Fraietta, J. A., Guo, L., McGettigan, S. E., Posey, A. D., Patel, P. R., Guedan, S., Scholler, J., Keith, B., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.021 · Cited by 1,230
Humanized mice for immune system investigation: progress, promise and challenges
Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V., & Greiner, D. L. (2012) · Nature Reviews Immunology · doi:10.1038/nri3311 · Cited by 979 · cited 1×
“…the immunodeficient xenograft mouse model is widely used to evaluate the efficacy of CAR-T therapy, it poorly predicts treatment-related clinical toxicities because these mice lack the same antigen that is targeted by CAR-T cells and bystander immune cells and reject human cell engraftment ( 32 ).”
c-Jun overexpression in CAR T cells induces exhaustion resistance
Lynn, R. C., Weber, E. W., Sotillo, E., Gennert, D., Xu, P., Good, Z., Anbunathan, H., Lattin, J., Jones, R., Tieu, V., et al. (2019) · Nature · doi:10.1038/s41586-019-1805-z · Cited by 891 · cited 1×
“Also, c-Jun deficiency mediates CAR-T cell dysfunction, and engineering CAR-T cells to overexpress c-Jun endows CAR-T cells with exhaustion resistance ( 29 ).”
NR4A transcription factors limit CAR T cell function in solid tumours
Chen, J., López-Moyado, I. F., Seo, H., Lio, C.-W. J., Hempleman, L. J., Sekiya, T., Yoshimura, A., Scott-Browne, J. P., & Rao, A. (2019) · Nature · doi:10.1038/s41586-019-0985-x · Cited by 874 · cited 1×
“NR4A1 has been identified as a key mediator of T cell hyporesponsiveness and limits CAR-T cell function in solid tumors ( 27 , 43 ).”
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
Brown, C. E., Badie, B., Barish, M. E., Weng, L., Ostberg, J. R., Chang, W.-C., Naranjo, A., Starr, R., Wagner, J., Wright, C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0428 · Cited by 764
Lamers, C. H., Sleijfer, S., van Steenbergen, S., van Elzakker, P., van Krimpen, B., Groot, C., Vulto, A., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 704 · cited 1×
“However, potential antigens targeted by CAR-T therapy are not restricted to tumor cells, and they are also expressed on normal tissues, leading to lethal on-target/off-tumor toxicity to normal tissues ( 5 , 6 ).”
Clinical lessons learned from the first leg of the CAR T cell journey
Majzner, R. G., & Mackall, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0564-6 · Cited by 636 · cited 1×
“Careful demonstration of the feasibility of the tumor antigen targeted by CAR-T cells, efficient intracellular signaling, and the delivery pathway of CAR-T cells are the focuses of researchers worldwide ( 37 ).”
Ghorashian, S., Kramer, A. M., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S. J., Casanovas-Company, J., Castro, F., Popova, B., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0549-5 · Cited by 632 · cited 1×
“The high affinity of the antigen-recognition domain should be responsible for antigen-induced fatal toxicity ( 50 , 51 ).”
Adusumilli, P. S., Cherkassky, L., Villena-Vargas, J., Colovos, C., Servais, E., Plotkin, J., Jones, D. R., & Sadelain, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3010162 · Cited by 572 · cited 2×
“Now, CAR-T therapies targeting TAAs, including disialoganglio-side (GD2), human epidermal growth factor receptor 2 (HER2), and mesothelin, have been demonstrated to be tolerable in preclinical and clinical studies ( 7 – 9 ).”
Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0159 · Cited by 565 · cited 1×
“The ability to recognize antigens is dependent on the affinity of scFv, while hyperactivation caused by excessive affinity can trigger T cell depletion and other toxicity ( 52 , 53 ).”
Heiss, M. M., Murawa, P., Koralewski, P., Kutarska, E., Kolesnik, O. O., Ivanchenko, V. V., Dudnichenko, A. S., Aleknaviciene, B., Razbadauskas, A., Gore, M., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25423 · Cited by 549 · cited 1×
“Various strategies targeting EpCAM molecules have demonstrated therapeutic potential in previous investigations ( 16 , 17 , 38 ); however, the clinical feasibility of CAR-T therapy targeting EpCAM is lacking.”
Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction
Liu, X., Wang, Y., Lu, H., Li, J., Yan, X., Xiao, M., Hao, J., Alekseev, A., Khong, H., Chen, T., et al. (2019) · Nature · doi:10.1038/s41586-019-0979-8 · Cited by 533
Self-citationPotent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas
Mount, C. W., Majzner, R. G., Sundaresh, S., Arnold, E. P., Kadapakkam, M., Haile, S., Labanieh, L., Hulleman, E., Woo, P. J., Rietberg, S. P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0006-x · Cited by 499 · cited 1×
“Now, CAR-T therapies targeting TAAs, including disialoganglio-side (GD2), human epidermal growth factor receptor 2 (HER2), and mesothelin, have been demonstrated to be tolerable in preclinical and clinical studies ( 7 – 9 ).”
Molecular and Transcriptional Basis of CD4+ T Cell Dysfunction during Chronic Infection
Crawford, A., Angelosanto, J. M., Kao, C., Doering, T. A., Odorizzi, P. M., Barnett, B. E., & Wherry, E. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.01.005 · Cited by 496
Salter, A. I., Ivey, R. G., Kennedy, J. J., Voillet, V., Rajan, A., Alderman, E. J., Voytovich, U. J., Lin, C., Sommermeyer, D., Liu, L., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat6753 · Cited by 495 · cited 1×
“A previous study re-ported that the signaling activation strength of CAR-T cells is a key determinant for the sustained activity of CAR-T cells ( 42 ).”
A safe and potent anti-CD19 CAR T cell therapy
Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N., Zhang, T., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0421-7 · Cited by 441 · cited 1×
“This may be attributed to the different kinetics of CAR-T cells in solid tumors and hematological malignancies ( 36 , 55 ).”
Self-citationCaruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 397 · cited 1×
“The ability to recognize antigens is dependent on the affinity of scFv, while hyperactivation caused by excessive affinity can trigger T cell depletion and other toxicity ( 52 , 53 ).”
A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains
Cappell, K. M., & Kochenderfer, J. N. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00530-z · Cited by 393
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Chong, E. A., Ruella, M., & Schuster, S. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2030164 · Cited by 339
Feng, K., Liu, Y., Guo, Y., Qiu, J., Wu, Z., Dai, H., Yang, Q., Wang, Y., & Han, W. (2018) · Protein & Cell · doi:10.1007/s13238-017-0440-4 · Cited by 326
Vitanza, N. A., Johnson, A. J., Wilson, A. L., Brown, C., Yokoyama, J. K., Künkele, A., Chang, C. A., Rawlings-Rhea, S., Huang, W., Seidel, K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01404-8 · Cited by 321
Brudno, J. N., Lam, N., Vanasse, D., Shen, Y.-W., Rose, J. J., Rossi, J., Xue, A., Bot, A., Scholler, N., Mikkilineni, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0737-3 · Cited by 311
Richman, S. A., Nunez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., Barrett, D. M., Grupp, S. A., & Milone, M. C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0211 · Cited by 267 · cited 1×
“The high affinity of the antigen-recognition domain should be responsible for antigen-induced fatal toxicity ( 50 , 51 ).”
Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226
LeibundGut-Landmann, S., Osorio, F., Brown, G. D., & Reis e Sousa, C. (2008) · Blood · doi:10.1182/blood-2008-05-158469 · Cited by 206
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells
Singh, N., Frey, N. V., Engels, B., Barrett, D. M., Shestova, O., Ravikumar, P., Cummins, K. D., Lee, Y. G., Pajarillo, R., Chun, I., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01326-5 · Cited by 196 · cited 1×
“Several studies have demonstrated that the therapeutic benefit of CAR-T cells might ultimately be dependent on optimal intracellular signaling transduced by the costimulatory molecules ( 20 , 39 ).”
Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors
Khan, M. S., Kirkwood, A., Tsigani, T., Garcia-Hernandez, J., Hartley, J. A., Caplin, M. E., & Meyer, T. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2905 · Cited by 185
Biasco, L., Izotova, N., Rivat, C., Ghorashian, S., Richardson, R., Guvenel, A., Hough, R. E., Wynn, R. F., Popova, B., Lopes, A., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00207-7 · Cited by 171 · cited 1×
“These findings suggested that Dectin-1 – stimulated EpCAM – CAR-T cells have appropriate persistence and sustained therapeutic efficacy ( 41 ), which has been further validated in xenograft models.”
Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors
Kosti, P., Opzoomer, J. W., Larios-Martinez, K. I., Henley-Smith, R., Scudamore, C. L., Okesola, M., Taher, M. Y. M., Davies, D. M., Muliaditan, T., Larcombe-Young, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100227 · Cited by 150 · cited 1×
“A previous study demonstrated that systemically infused CAR-T cells accumulated in the lung, liver, and other critical organs and resulted in on-target/off-tumor toxicity ( 34 ).”
Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker
Moldenhauer, G., Momburg, F., Möller, P., Schwartz, R., & Hämmerling, G. J. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.276 · Cited by 136 · cited 2×
“Considering the widespread expression of EpCAM in gastric cancer, colon cancer, and other solid tumors ( 10 ) and the excellent antitumor activity and safety of EpCAM – CAR-T cells in preclinical research ( 18 , 35 ), we then initiated a phase 1 clinical study of Dectin-1 – administrated EpCAM –…”
Kowalski, M. M., Guindon, J., Louise, B., Moore, C., Entwistle, J., Cizeau, J., Jewett, M. A. S., & MacDonald, G. C. (2012) · The Journal of Urology · doi:10.1016/j.juro.2012.07.020 · Cited by 122
Jäger, M., Schoberth, A., Ruf, P., Hess, J., Hennig, M., Schmalfeldt, B., Wimberger, P., Ströhlein, M., Theissen, B., Heiss, M. M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2235 · Cited by 117 · cited 2×
“Many immunotherapies targeting EpCAM, including adecatumu-mab (anti-EpCAM), the trifunctional antibody catumaxomab (anti-EpCAM and anti-CD3), and oportuzumab monatox, have shown promising clinical benefits for patients with EpCAM-ex-pressing tumors ( 14 – 17 ).”
Zhang, H., Li, F., Cao, J., Wang, X., Cheng, H., Qi, K., Wang, G., Xu, K., Zheng, J., Fu, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba7308 · Cited by 115 · cited 1×
“Several studies have demonstrated that the therapeutic benefit of CAR-T cells might ultimately be dependent on optimal intracellular signaling transduced by the costimulatory molecules ( 20 , 39 ).”
Zhang, B.-L., Li, D., Gong, Y.-L., Huang, Y., Qin, D.-Y., Jiang, L., Liang, X., Yang, X., Gou, H.-F., Wang, Y.-S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.229 · Cited by 88
Self-citationWimberger, P., Gilet, H., Gonschior, A. K., Heiss, M. M., Moehler, M. H., Oskay-Oezcelik, G., Al-Batran, S.-E., Schmalfeldt, B., Schmittel, A. H., Schulze, E., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds178 · Cited by 80
Yang, Y., McCloskey, J. E., Yang, H., Puc, J., Alcaina, Y., Vedvyas, Y., Gallegos, A. A. G., Ortíz-Sánchez, E., de Stanchina, E., Min, I. M., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0062 · Cited by 65 · cited 2×
“Although many preclinical investigations of EpCAM – CAR-T therapy have shown the inhibition of tumor growth and metastasis in animal models ( 18 ), clinical studies presenting detailed evaluations of the safety and efficacy of EpCAM – CAR-T therapy are lacking.”
Self-citationSchmidt, M., Rüttinger, D., Sebastian, M., Hanusch, C. A., Marschner, N. W., Baeuerle, P. A., Wolf, A., Göppel, G., Oruzio, D. V., Schlimok, G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr625 · Cited by 54 · cited 1×
“Many immunotherapies targeting EpCAM, including adecatumu-mab (anti-EpCAM), the trifunctional antibody catumaxomab (anti-EpCAM and anti-CD3), and oportuzumab monatox, have shown promising clinical benefits for patients with EpCAM-ex-pressing tumors ( 14 – 17 ).”
Qin, D., Li, D., Zhang, B., Chen, Y., Liao, X., Li, X., Alexander, P. B., Wang, Y., & Li, Q.-J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1806009 · Cited by 49
Self-citationCD4+ T-cell survival in the GI tract requires dectin-1 during fungal infection
Drummond, R. A., Dambuza, I. M., Vautier, S., Taylor, J. A., Reid, D. M., Bain, C. C., Underhill, D. M., Masopust, D., Kaplan, D. H., & Brown, G. D. (2016) · Mucosal Immunology · doi:10.1038/mi.2015.79 · Cited by 47
Ghosn, M., Cheema, W., Zhu, A., Livschitz, J., Maybody, M., Boas, F. E., Santos, E., Kim, D., Beattie, J. A., Offin, M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.003 · Cited by 32 · cited 1×
“In addition, there is no obvious difference in safety for these two CAR-T cell delivery strategies in the corresponding clinical research ( 44 ).”
Two cases of T cell lymphoma following Piggybac-mediated CAR T cell therapy
Schambach, A., Morgan, M. A., & Fehse, B. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.013 · Cited by 28
Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient
Hu, G., Li, G., Wen, W. X., Ding, W. Y., Zhou, Z., Zheng, Y., Huang, T., Ren, J., Chen, R., Zhu, D., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956593 · Cited by 21 · cited 1×
“Also, the therapeutic potential of local delivery pathways, such as intertumoral injection ( 45 ) and intracranial injection ( 46 , 47 ), has been validated in previous studies.”
Distinct functions of CAR-T cells possessing a dectin-1 intracellular signaling domain
Liang, X., Huang, Y., Li, D., Yang, X., Jiang, L., Zhou, W., Su, J., Chen, N., & Wang, W. (2021) · Gene Therapy · doi:10.1038/s41434-021-00257-7 · Cited by 11 · cited 1×
“In a preliminary study of this CAR construct, our team demonstrated that HER2-specific CAR-T cells bearing the Dectin-1 costimulatory domain exhibited different phenotypes and biological functions from those of CD28 CAR-T cells ( 40 ).”
Self-citation
Cited by
Understanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 167
“…a phase I trial evaluating CAR T cells targeting the CSC surface marker EpCAM reported manageable toxicities and durable responses in patients with advanced-stage EpCAM + epithelial tumours, with 2 of 12 patients having a partial response and 3 others having stable disease for >23 months 315 .”
Enhancing the safety of CAR-T cell therapy: Synthetic genetic switch for spatiotemporal control
Lu, L., Xie, M., Yang, B., Zhao, W., & Cao, J. (2024) · Science Advances · doi:10.1126/sciadv.adj6251 · Cited by 129
Viral oncogenesis in cancer: from mechanisms to therapeutics
Xiao, Q., Liu, Y., Li, T., Wang, C., He, S., Zhai, L., Yang, Z., Zhang, X., Wu, Y., & Liu, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02197-9 · Cited by 128
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
Khan, S. H., Choi, Y., Veena, M. S., Lee, J. K., & Shin, D. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489827 · Cited by 96
“A CAR T cell trial targeting epithelial cell adhesion molecule (EpCAM) is ongoing now (NCT02915445) (167).”
Metadata
- Authors
- Li, D., Guo, X., Yang, K., Yang, Y., Zhou, W., Huang, Y., Liang, X., Su, J., Jiang, L., Li, J., Fu, M., He, H., Yang, J., Shi, H., Yang, H., Tong, A., Chen, N., Hu, J., Xu, Q., Wei, Y.-Q., & Wang, W.
- Affiliations
- Sichuan University (CN)
- Shanghai Tenth People's Hospital (CN)
- Sun Yat-sen University (CN)
- Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu, China.
- Corresponding author
- Li, Dan
- Guo, Xianling
- Yang, Kun
- Chen, Nianyong
- Xu, Qing
- Wei, Yu-Quan
- Wang, Wei
- ORCID
- Venue
- Science Advances
- Published
- 2023-12
- Volume
- 9
- Issue
- 48
- Pages
- eadg9721-eadg9721
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC10691766
- OpenAlex
- W4389232854
- Cited by
- 97
- References
- 57
- Citations by year
- 2026: 31 · 2025: 49 · 2024: 17
- FWCI
- 11.78
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81972878, 82172733)
- National Key Research and Development Program of China (2016YFC1303403, 2020YFC0860200)
- Key Research and Development Program of Sichuan Province (2022ZDZX0024)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- EpCAM, CAR T-cell therapy, solid tumors, epithelial tumors, antitumor immunity, xenograft models, humanized mice, treatment toxicity, progression-free survival, tumor markers
- MeSH terms
- Epithelial Cell Adhesion Molecule, Receptors, Chimeric Antigen, Animals, Humans, Immunotherapy, Neoplasms, Glandular and Epithelial, T-Lymphocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.